The c-Met tyrosine kinase receptor and its ligand, Hepatocyte Growth Factor/ Scatter Factor, have been implicated in human cancer. We have previously described that the transgenic expression of a truncated form of human c-Met (cyto-Met) in the liver confers resistance to several apoptotic stimuli. Here we show the impact of cyto-Met expression on liver proliferation and transformation. Despite a sixfold increase of hepatocyte proliferation, adult transgenic livers displayed normal size and architecture. We present evidence showing that activation of TGF-b1 signalling controls the liver mass in cyto-Met mice. The oncogenic potential of cyto-Met was further assessed in the context of c-Myc-induced hepatocarcinogenesis, using WHV/c-Myc transgenic mice. Co-expression of cyto-Met and c-Myc further enhanced hepatocyte proliferation and caused a dramatic acceleration of the Myc-induced tumorigenesis, leading to the emergence of hepatocarcinomas in 3 ± 4-month-old animals. Importantly, the TGF-b receptor type II expression was strongly downregulated in most tumours, indicating that impairment of TGF-b1-mediated growth inhibition plays a major role in accelerated neoplastic development. The strong potential of cyto-Met for oncogenic cooperation without direct transforming activity designates cyto-Met mice as an ideal tool for studying the early steps of multistage hepatocarcinogenesis and for identi®cation of prognostic markers of transformation.
Introduction
Receptor tyrosine protein kinases (RTPKs) play important roles in signal transduction and in cell proliferation and their abnormal activation may lead to malignant transformation. The transmembrane RTPK Met is the high anity receptor of the Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) (Bottaro et al., 1991) . This cytokine elicits varieties of responses in epithelial and endothelial cells, including cell proliferation, motility, extracellular matrix invasion, formation of tubular structures (reviewed by Rubin et al., 1993) and protection from apoptosis (Bardelli et al., 1996) . These pleiotropic eects are mediated by the recruitment of multiple intracellular signal transducers to a single docking site (Ponzetto et al., 1994) . Furthermore, HGF/Met acts as a paracrine regulator of morphogenesis in various dierentiation programmes and plays a pivotal role in liver development, as revealed by early hepatic involution in mouse embryos harbouring a HGF-null mutation (Schmidt et al., 1995; Bladt et al., 1995) .
Aberrant HGF/Met signalling is involved in the development of several human cancers and in their metastatic phenotype (Jeers et al., 1996; . Overexpression of the full-length receptor has been found in numerous tumours and cell lines and appears to be ampli®ed during the transition from primary tumours to metastasis (Di Renzo et al., 1995) . Moreover, mutations in the c-met gene have been implicated in malignancy, either by increasing cell growth ability or through protection of cells from apoptosis (Giordano et al., 2000) . However, the precise role of HGF and its receptor in liver cancer remains controversial. In some transgenic strains, constitutive activation of HGF in hepatocytes promoted liver enlargement and carcinogenesis (Sakata et al., 1996) . Conversely in other strains, HGF expression had no pathological eect and it was shown to inhibit c-Mycinduced liver carcinogenesis (Shiota et al., 1994; Santoni-Rugiu et al., 1996) . This apparent discrepancy might be dosage-related, since dierent concentrations of HGF have opposite eects on the growth of liver cell lines (Von Schweinitz et al., 2000) .
Molecular dissection of the Met receptor has clari®ed the function of single regions in in vitro systems. It has been shown that the Met cytoplasmic domain, truncated immediately below the transmembrane region, acquires constitutive tyrosine kinase activity, but exhibits only weak transforming potential . In contrast, replacement of the Met extracellular and juxtamembrane domains by a dimerization motif of the TRP gene causes constitutive kinase activation leading to cellular transformation (Rodrigues and Park, 1993) . In order to study the role of Met in liver physiopathology, we have developed a transgenic mouse model expressing a truncated form of the human receptor (cyto-Met) (Amicone et al., 1995) . We have shown that cyto-Met transgene expression confers resistance to apoptotic stimuli in vivo and permits the establishment of immortalized, non-transformed hepatocyte cell lines (Amicone et al., 1997) .
Here we report that the cyto-Met transgene triggers constitutive hepatocyte proliferation that does not result in liver hyperplasia or malignant transformation during the entire mouse life span. Our data indicate that Transforming Growth Factor (TGF)-b1 signalling plays a major role in the control of liver mass homeostasis in cyto-Met mice. To assess whether Met-induced hepatocyte proliferation provides a favourable environment for oncogene cooperation, we have generated a double transgenic strain by crossing cyto-Met mice with WHV/c-Myc oncomice. The WHV/c-Myc mice carry a mutated c-myc allele isolated from a woodchuck liver tumour, in which woodchuck hepatitis virus (WHV) DNA was integrated upstream of the ®rst c-myc exon. In these animals, liver-speci®c expression of the transgene is associated with the invariable development of hepatocellular carcinoma (HCC) before 18 months of age (Etiemble et al., 1994) . Coincident expression of Met and Myc further increased the proliferative activity of liver cells, and exerted a potent synergistic eect on the tumoural process, leading to the emergence of HCCs within 3 ± 4 months. In this model, impaired responsiveness to TGF-b1 through downregulation of the TGF-b1 type II receptor (TbRII) may contribute in acceleration of cMyc-induced carcinogenesis.
Results

Expression of the cyto-Met transgene in mouse liver
The establishment of transgenic mice expressing a truncated form of human Met which contains only the cytoplasmic and juxtamembrane domains (designated cyto-Met) has been described previously (Amicone et al., 1995) . Brie¯y, the transgene was obtained by incorporating a truncated cDNA of the human c-met gene in the entire a1-antitrypsin (A1AT) transcriptional unit. We have shown that it is expressed in adult animals in a liver-speci®c and abundant manner (Amicone et al., 1995) , and that the protein is detectable by immunostaining of liver sections only in perivenular and periportal areas (Amicone et al., 1995 (Amicone et al., , 1997 . To better de®ne the expression pro®le of the transgene in liver zones, we performed in situ hybridization on the liver of a 6-month-old transgenic mouse using a speci®c human c-met antisense cRNA probe (nucleotides 3589 ± 4626). As shown in Figure 1 , this technique highlighted zonality of the transgene expression, reproducing the expression pattern of the A1At gene in the liver, with predominant location around the portal space (Jungermann and Kietzmann, 1996) .
Constitutive hepatic proliferation in the absence of hyperplasia or cellular transformation
The well-known mitogenic eect of the HGF receptor activation prompted us to investigate possible alterations in the liver proliferative state in cyto-Met mice. Cells undergoing DNA synthesis were scored in transgenic and age-matched wild-type animals by immunohistochemical detection of incorporated Bromodeoxyuridine (BrdU). BrdU was administrated in drinking water for 1 week to 10 transgenic and seven wild-type animals older than 4 months. As shown in Figure 2 , cyto-Met transgenic mice showed a constitutively high hepatocyte proliferation index, with intense staining in 5.8%+1.8 of hepatocytes, while control mice showed labelling mainly in non-parenchymal cells and in only 0.9%+0.5 of hepatocytes.
In spite of increased basal proliferation rate, cytoMet mice did not exhibit altered hepatic index (liver weight/body weight ratio), cellular hyperplasia, liver lesions or hepatocyte transformation. None of 200 animals analysed, including 32 mice older than 18 months, showed hepatic alterations related to transgene expression. In particular, the hepatic index, measured in groups of transgenic and age-matched wild-type animals, did not show any signi®cant dierences (cytoMet mice 4.13%+0.14, wild-type mice 3.94+0.24; P40.9, Student t-test).
Liver mass homeostatic control in cyto-Met transgenic mice
The unaltered hepatic index in transgenic animals suggested that the liver mass was eciently controlled by a homeostatic compensatory mechanism. Accordingly, we analysed the hepatic basal apoptotic activity by Terminal transferase-mediated dUTP Nick EndLabelling (TUNEL) in 4-month-old transgenic and non-transgenic animals (four animals for each group). DNA fragmentation was found in about 0.22% (+0.06) parenchymal cells in transgenic mice while being barely detectable in wild-type animals. Notably, the TUNEL assay labelled rare clusters of cells randomly distributed in liver lobules (Figure 3) . The apoptosis seems the only cause of maintained liver 
Activation of TGF-b1 in the livers of cyto-Met mice
We have previously shown that the Fas-mediated apoptotic pathway was impaired in the liver of transgenic cyto-Met animals (Amicone et al., 1997) . This suggested that Fas-independent apoptotic pathways might control the liver mass. An alternative pathway could be driven by TGF-b1. Indeed, TGF-b1 is a potent inhibitor of hepatocyte growth and it has been shown to induce apoptosis in hepatocytes and in hepatoma cell lines (Fausto et al., 1995; ShulteHermann et al., 1995) .
We investigated the expression pattern of TGF-b1 in transgenic livers. Immunohistochemical analysis revealed intense TGF-b1 expression in transgenic livers, that accumulated the cytokine mainly in periportal areas and in rare scattered hepatocytes distributed over the liver lobes (Figure 4a, b) . In striking contrast, TGFb1 labelling was very faint in control wild-type livers ( Figure 4c) .
Activation of the TGF-b1 pathway results in Smad2 phosphorylation followed by Smad2 ± Smad4 complex translocation to the nucleus (Nakao et al., 1997) . We therefore compared transgenic and wild-type livers for Smad2 phosphorylation levels. As shown in Figure 4d , Western blot analysis demonstrated increased phosphorylation of the receptor-activated Smad2 in cytoMet livers compared to the wild-type controls. Accordingly with these observations, nuclear accumulation of Smad4 was found speci®cally in cyto-Met liver extracts (Figure 4e ). Constitutive activation of Smad proteins in cyto-Met transgenic livers might not depend exclusively on overexpression of TGF-b1, since tyrosine kinase receptors have been described to activate this pathway (de Caestecker et al., 1998) .
Cyto-Met cooperates with c-Myc in hepatocarcinogenesis
In view of the multifactorial genesis of cancer, the possibility that constitutive hepatocyte proliferation triggered by cyto-Met expression could collaborate with the c-myc oncogene, a potent inductor of liver carcinogenesis, was tested. To this end, a double transgenic strain was established by breeding cytoMet transgenics with WHV/c-Myc transgenic mice. WHV/c-Myc transgenics carry a mutated c-myc allele isolated from a woodchuck liver tumour and develop hepatocellular carcinoma (HCC) with an average latency of 8 ± 12 months (Etiemble et al., 1994) .
The kinetics of tumour onset and progression were analysed in 75 mice sacri®ced at various ages by macroscopic and microscopic examination. As shown in Figure 5a , the simultaneous expression of the two transgenes caused a dramatic acceleration of hepatocarcinogenesis compared with single WHV/c-Myc transgenics. Indeed, 100% of double transgenic males and 75% of females showed macroscopic liver tumours as early as 4 months after birth, while all Myc animals analysed remained free of tumours until the age of 6 months, and only one half developed HCC after 1 year. Histological analysis of 2.5-month-old bi-transgenic mice showed an obvious liver pathology characterized by multiple foci of dysplasia with enlarged hepatocytes displaying altered nucleus/cytoplasm ratio, nuclear polymetrism and polymorphism (Figure 5b ). These histological alterations were also present in age-matched WHV/c-Myc transgenics but with markedly reduced extent and severity. Most 3.5-month-old bi-transgenic mice had macroscopic lesions (often unique), 1 ± 2 mm in diameter, that were already histologically con®rmed HCCs with a moderate grade of cellular dierentiation (Figure 5c ). In contrast with WHV/c-Myc mice, hepatocellular adenomas or benign hyperplastic nodules were never observed in bi-transgenic animals. At 5 months of age and later, a large percentage of mice developed HCCs invading almost the entire liver, with minimal regions of the organ remaining free of neoplasms (Figure 5d ). These tumours varied from moderately dierentiated to poorly dierentiated HCCs, while a majority of tumours from WHV/c-Myc mice consisted of trabecular, well dierentiated HCCs. Thus, in this model, not only the kinetics but also the extent and severity of liver lesions induced by c-Myc were greatly enhanced in cyto-Met expressing animals. In agreement with the tumourigenic process in WHV/cMyc mice (Etiemble et al., 1994) but in contrast with other models of epithelial tumours (Grippo and Sandgren, 2000; Jansen et al., 2001) , metastasis of the primary liver tumours were never observed, indicating that cyto-Met expression did not confer invasive potential to the transformed hepatocytes. Consistent with the strict liver-speci®city of transgene expression, none of these mice, like wild-type controls, developed cancers in other organs.
Expression of the WHV/c-Myc and cyto-Met transgenes in single and double transgenic livers
Because HGF/Met signalling has been shown to activate transcription of the c-myc gene in epithelial cells (Desiderio et al., 1998; Cliord et al., 1998) , the rapid emergence of liver tumours in double transgenic mice could result from enhanced expression of the WHV/c-Myc transgene or endogenous murine c-myc. We therefore investigated c-myc expression by Northern blot analysis of RNA extracted from WHV/c-Myc transgenic and Myc/Met bi-transgenic livers, using probes of woodchuck and murine c-myc exon 1 under stringent hybridization conditions. As shown in Figure  6 , WHV/c-Myc transgene expression was not detectable in untransformed adult liver of double Myc/Met transgenics as well as in single WHV/c-Myc animals. In tumours, the WHV/c-Myc transgene was expressed at comparable levels in single and double transgenics. These data are in agreement with previous reports showing that the expression of WHV/c-Myc transgene is barely detectable in the adult liver, and is strongly activated at early steps of tumour emergence (Etiemble et al., 1994; Liu et al., 1997) . Furthermore, expression of the endogenous c-myc was not modi®ed in double transgenics and remained at low, barely detectable levels (data not shown). Thus, in our model, acceleration of the Myc-induced tumourigenic process by cytoMet was not associated with constitutive upregulation of c-myc. In addition, Northern blot analysis indicated that the cyto-Met transgene was expressed at similar levels in tumours and in normal liver of double transgenic animals ( Figure 6 ).
Proliferative and apoptotic rates in single and double transgenic mice
Increased proliferation of liver cells at pretumoural stages is a hallmark of liver tumorigenesis (Webber et al., 1994; Huang and Chisari, 1995) . Since both cyto-Met and WHV/c-Myc transgenes aect hepatocyte proliferation (this study and Terradillos et al., 1997), we next scored the mitotic index in normal liver parenchyma of single and bi-transgenic animals. Immunostaining of liver sections with anti-Proliferating Cellular Nuclear Antigen (PCNA) antibody was performed in Myc, Met and Myc/Met animals at 80 days of age. At this period, all animals were tumour-free, although preneoplastic liver lesions of various intensity were present in all Myc and Myc/ Met mice. While single cyto-Met or Myc transgenic livers showed comparable rates of PCNA-positive hepatocytes (2.1%+0.8 versus 3.2%+2.2), the hepatocyte proliferative index was strikingly increased in Myc/Met double transgenic mice (14.9%+3.6, P50.02, Mann ± Whitney test) ( Figure  7a ). It is not surprising that the proliferation rates in cyto-Met mice measured by PCNA is lower than that measured by BrdU incorporation (Figure 2 ) since the techniques are based on very dierent labelling time course.
These data clearly demonstrate the strong synergistic eect of this transgenic combination in the induction of liver cell proliferation at preneoplastic stages.
Earlier studies of liver cell apoptosis in WHV/c-Myc mice at various ages using the TUNEL method have revealed a moderate increase of apoptotic indexes compared to wild-type animals (Liu et al., 1997) . To determine whether the strong proliferative activity of liver parenchymal cells in double transgenic animals was compensated by augmented apoptotic cell death, we performed a comparative analysis of the spontaneous cell death rate in livers from Met, Myc and Myc/ Met transgenics. Apoptotic indexes measured by the TUNEL assay in the livers of 80-day-old animals were not dramatically dierent among the three groups of transgenic animals (0.20%+0.07 for cyto-Met, 0.43%+0.11 for WHV/Myc and 0.26%+0.14 for double transgenic livers) (Figure 7b ). Thus, despite considerably higher proliferation in double transgenic livers, apoptosis was maintained at slightly lower levels than in single Myc livers (P50.05, Mann ± Whitney test).
Taken together, these data suggest that enhanced proliferative activity, only partially compensated by apoptotic death at preneoplastic stages, plays a major role in accelerating tumour onset in the double transgenics.
Impairment of TGF-b1 signalling in tumour cells of double transgenic mice
It has been shown in dierent transgenic models that reduced TGF-b1 signalling may provide a growth advantage to preneoplastic hepatocytes and tumour cells (Santoni-Rugiu et al., 1996 . Unresponsiveness to TGF-b1 growth inhibition combined with the Figure 8c , the phosphorylation of Smad2 is clearly downregulated in most tumour extracts compared to the surrounding normal tissue.
In order to investigate the molecular mechanisms responsible for impairment of TGF-b1 signalling in transformed cells, TbRII expression was analysed in tumours and normal livers by immunohistochemistry. As illustrated in Figure 8a ,b, TbRII immunostaining was markedly reduced or totally absent in most tumour cells of the Myc/Met mice analysed, in striking contrast with the strong expression level of the receptor in adjacent non-tumoural parenchymal cells. These data, together with previously reported observations in TGF-a/Myc transgenics (Santoni-Rugiu et al., 1999), implicate downregulation of TbRII expression and the development of TGF-b1 resistance as a crucial step in murine hepatocarcinogenesis.
Finally, in order to verify whether the potentiation of Myc oncogenesis may also depend from survival signals induced by cyto-Met, we analysed the phosphorylation of Akt and its substrate Bad by Western blot. Both proteins are known to mediate the antiapoptotic activity and survival eects of HGF/Met (Xiao et al., 2001) . No dierence have been observed between transgenic, bi-transgenic and wild-type livers (data not shown).
Discussion
In this report, we have shown that liver expression of a truncated form of c-Met stimulates the hepatocyte turn-over in a way that does not impair the homeostatic control of liver mass nor causes hepatocellular transformation. These conditions, however, strongly synergize with unregulated expression of cMyc to induce a dramatic acceleration of liver tumorigenesis.
We previously reported that hepatocytes expressing the cyto-Met transgene were highly resistant to Fasmediated apoptosis in vivo and to various apoptotic stimuli in vitro (Amicone et al., 1997) . Surprisingly, our present data show that, despite constitutive hepatocyte proliferation, the hepatic index (liver weight/body weight) of cyto-Met mice remained unaltered, thus implying a ®ne regulatory mechanism that guarantees a perfect balance between cell proliferation and cell death. Apoptosis is known to regulate liver homeostasis in several situations. Cell loss through apoptosis is responsible for undoing the`overshoot' of cell regeneration after partial hepatectomy and for restoring adequate liver mass after removal of mitogenic stimuli, such as lead nitrate (Columbano et al., 1984) and cyproterone acetate (Bursch et al., 1986) . Our ®ndings that TGF-b1 expression, Smad2 phosphorylation and Smad4 nuclear translocation are markedly activated in cyto-Met livers strongly implicate TGF-b1 signalling in compensatory apoptosis. By immunostaining, we show that both the TGF-b1 accumulating and the cyto-Met expressing hepatocytes are mainly (but not exclusively) located in periportal liver zones. To explain the eect of the opposite stimuli exerted by cyto-Met and TGF-b1 on hepatocyte homeostasis, we propose that TGFb1-mediated growth inhibition and apoptosis (resulting from a paracrine and/or autocrine mechanism) may be in¯uenced by hepatocyte localization; this is in agreement with previous published data. In fact it was shown that in regeneration TGF-b1 accumulated in periportal hepatocytes inducing restrain of DNA synthesis (Jirtle et al., 1991) , while in experimental model of liver apoptosis the programmed cell death seems to be located mainly in the hepatocytes nearest the central vein (older hepatocytes) (Benedetti et al., 1988) . Accordingly, we never observed BrdU incorporation or TUNEL positivity in periportal hepatocytes. We would underline that the dierent proliferation and apoptotic rates we observed are compatible with the liver mass maintenance; TUNEL method, in fact, revealing DNA fragmentation, underestimates the eective apoptotic rate because, in vivo, apoptotic cells are quickly phagocyted by macrophages. Moreover, the short half-life of the dierent apoptotic stages combined with the asynchrony of the process in the cells may reveal only a part of the hepatocytes with fragmented DNA.
So far we discussed the role of TGF-b1 as growth inhibitor and apoptotic inductor in our transgenic model. As matter as concerned its tumour suppressor role, it is known to operate in human cancer and might well be implicated in repressing malignant transformation in cyto-Met livers. Smad4/DPC4 is a tumour suppressor frequently inactivated in pancreatic and gastrointestinal cancers, and activation of Smadresponsive genes might be responsible for the maintenance of a normal phenotype in cyto-Met mice. Importantly, the constitutive nuclear translocation of the Smad4 protein, a key mediator of the TGF-b1 signal, in cyto-Met liver is an interesting observation, although it might not be univocally related to the TGF-b1 pathway. In fact, we also detected nuclear Smad4 in TbRII-negative liver tumours from Myc/Met mice (data not shown). The data published by de Caestecker et al. (1998) on the cross-talk between HGF and TGF-b1 molecular pathways may provide an alternative model, in which nuclear translocation of Smad4 might also be triggered by c-Met-induced activation of Smad2. In view of the complex interplay between signalling cascades generated by both classes of agents, an interesting issue is whether activated cMet acts synergistically or antagonistically with the signals emanating from TGF-b1.
Considering the absence of pathological eect of the cyto-Met transgene, the dramatic acceleration of liver tumour onset induced by co-expression of cyto-Met and Myc was particularly striking. The c-myc oncogene plays a central role in cancer biology, as a key regulator of cell growth, apoptosis and metabolism, and a potent integrator of the cell cycle machinery (Dang et al., 1999) . Overexpression of c-Myc has been observed in a majority of human HCCs, and deregulated expression of c-Myc in the transgenic mouse liver is known to confer a high predisposition to cancer development. Here we show that the proliferative activity of bi-transgenic livers is enhanced by ®vefold compared to either WHV/c-myc or cytoMet single transgenic livers at preneoplastic stages. By contrast, the apoptotic index was not markedly modi®ed, showing rather intermediate values. Taken together, these data suggest that co-expression of cytoMet and Myc further deregulates the cell cycle machinery, leading to enhanced proliferation that is not compensated by an increased rate of apoptosis. Loss of TGF-b1 responsiveness through down-regulation of the TbRII in preneoplastic liver lesions as well as in a majority of liver tumours from Myc/Met mice might account for unregulated growth and premature transformation. In previous reports, transgenic models in which TGF-a cooperates with c-Myc in liver oncogenesis have been extensively investigated, showing similar features and suggesting common pathways with the Myc/Met collaboration described in the present work (Santoni-Rugiu et al., 1996) . Indeed in the livers of TGF-a/Myc animals proliferation is (Amicone et al., 1997) before (7) and after (+) TGF-b1 in vitro treatment greatly enhanced and the levels of mature TGF-b1 are increased from the early stages of tumorigenesis (Santoni-Rugiu et al., 1999) . Moreover the recent report of Jo et al. (2000) describing TGF-a mediated c-Met activation in absence of HGF, may provide evidence for a direct cross-talk between TGF-a and cMet pathways. Furthermore, it has been shown that the overexpression of TGF-b1 can provide a growth advantage to the (pre)neoplastic cells with reduced sensitivity to this cytokine and cause a their fast progression towards a malignant phenotype (Factor et al., 1997; Santoni-Rugiu et al., 1999) .
In conclusion, the Myc/Met bi-transgenic mice represent one of the most powerful models of oncogenic cooperation described until now. While several oncogenes and growth factors have been shown to cooperate with c-Myc in hepatocarcinogenesis, cytoMet is one of the rare examples of a gene with a potent cooperation activity in the absence of intrinsic transforming capability. Regarding this last aspect, the cyto-Met mice appear as a useful tool to study the ®rst steps of the multistage carcinogenesis and to identify molecular and cellular prognostic markers of transformation.
Material and methods
Transgenic mice
Details on the construction of the cyto-Met and WHV/c-Myc transgenes have been described previously (Amicone et al., 1995; Etiemble et al., 1994) . Expression of both transgenes was strictly liver-speci®c. Heterozygous cyto-Met and WHV/ c-Myc mice were crossed to generate an experimental cohort of single and double transgenic animals. Animal care and sacri®ce were performed according to the EEC guidelines. Mice were sacri®ced at regular intervals, body weights were recorded and livers were resected, weighted and examined for gross and microscopic lesions. For hepatic index assessment the liver weight/body weight ratio was calculated for experimental groups of cyto-Met transgenic and wt animals (20 animals for group) and statistical dierences between groups were assessed with the Student t-test. For histopathological analysis, liver samples were ®xed in 4% (w/v) buered paraformaldehyde overnight and embedded in paran. Fivemm thick sections were stained with haematoxylin and eosin.
RNA analysis
In situ hybridization (ISH) was performed according to Bloch (1993) . Brie¯y, liver samples were ®xed in 4% paraformaldehyde in phosphate-buered saline (PBS) for 4 h at 48C, dehydrated in graded sucrose (7.5 ± 30%) in PBS for 4 h at 48C, frozen, and 10 mm cryosections were cut. The tissue sections were ®xed in paraformaldehyde, digested with proteinase K (4 mg/ml), washed with PBS, post ®xed in paraformaldehyde, treated with triethanolamine/acetic anhydride (0.25%), washed in PBS and immersed in 26SSC.
Human met riboprobes were transcribed from pBS-Met1 that contains 0.9 kb of human met cDNA sequences (nucleotides 3589 ± 4626)¯anked by promoter sequences for T7 and T3 RNA polymerases. Digoxigenin-labelled sense and antisense cRNA transcripts were synthesized from linearized cDNA templates using Riboprobe Combination System T3/ T7 (Promega), according to manufacturer's conditions. The tissue slides were hybridized overnight at 578C in 50% deionized formamide, 46SSC, 16Denhardt's, 1 mg/ml salmon sperm DNA, 1 mg/ml tRNA, and 1.5 ± 3 ng/ml DIG-labelled cRNA probe. The tissue slides were washed at 378C in 2x SSC and treated with 20 mg/ml RNase A at 378C for 30 min. Following stringent washes at 658C in 26SSC and 0.16SSC for 1 h, the slides were analysed by immunohistochemistry, using alkaline phosphatase-conjugated anti-digoxigenin Fab fragments (Roche Molecular Biochemical) and 5-bromo-cloro-3-indolyl phosphate/nitro blue tetrazolium. Sense cRNA probes were used as control of hybridization speci®city.
For Northern blot analysis, total RNA was extracted from liver tissues according to standard protocols. RNA samples (20 mg per lane) were resolved by electrophoresis in 1% agarose ± 1.85 M formaldehyde gels and blotted onto nylon membranes (Amersham). Blots were hybridized with 32 Plabelled speci®c probes [woodchuck c-myc exon 1 (Etiemble et al., 1994) and cyto-Met (Amicone et al., 1995) at 428C in 50% formamide buer (Hybrisol, Oncor).
BrdU labelling index
BrdU (Sigma) was used at a concentration of 1 mg/ml in regular drinking water together with 1% Sucrose (Sigma) during 1 week. The bottles were protected from light and the water exchanged every 3 ± 4 days.
Liver samples were ®xed in 10% formalin and embedded in paran. Tissue sections were dewaxed, treated with 2N HCl, incubated with trypsin (0.1%) for 20 min and then with normal goat serum for 20 min at room temperature. The sections were then incubated for 2 h with a monoclonal antiBrdU antibody (Roche Molecular Biochemicals), followed by alkaline phosphatase-labelled goat anti-mouse IgG (Dako) and BrdU incorporation into nuclei was determined with the Fast Red Substrate System (Dako). Sections were counterstained with haematoxylin. At least 3000 hepatocytes were scored for each animal. At least seven animals were scored in each experimental group, and statistical dierences between groups were assessed with the Student t-test.
DNA fragmentation and apoptosis assay
In situ detection of apoptotic hepatocytes was performed in mouse liver samples as described . Liver cells undergoing apoptosis were revealed by in situ nickend labelling of nucleosomal DNA (TUNEL) as described previously by Gavrieli et al. (1992) . Fragmented DNA was end-labelled with biotinylated-dUTP by terminal deoxynucleotide transferase and detected with ExtrAvidin-TRITC conjugate (Sigma). The in situ cell death detection kit (Boehringer-Mannheim, Mannheim, Germany) was alternatively used in some experiments. Tissues were counterstained with haematoxylin. For apoptotic quanti®cation, 20 consecutive optic ®elds were counted. Only stained nuclei showing typically condensed chromatin were selected. Apoptotic rates are plotted as the percentage of TUNELpositive hepatocytes. The Mann ± Whitney test was used for statistical analysis.
Immunohistochemistry
The expression of PCNA, TGF-b1 and TbRII was detected on formalin-®xed, paran-embedded liver sections, using a mouse anti-PCNA monoclonal antibody (sc-56, Santa Cruz Biotechnology), a rabbit anti-TGF-b1 polyclonal antibody (sc-146, Santa Cruz Biotechnology) and a goat anti-TbRII polyclonal antibody (L-21, Santa Cruz Biotechnology) respectively. The liver sections were dewaxed and treated with 1% H 2 O 2 to block the endogenous peroxidase activity. After high temperature antigen retrieval in 10 mM citrate buer, pH 6.0, sections were incubated with primary antibodies, followed by incubation with biotinylated antimouse (or anti-rabbit or anti-goat) IgG and avidin ± biotin peroxidase complex. The binding of the antibodies was revealed by diaminobenzidine and the sections were counterstained with haematoxylin.
Western blotting
The liver samples were homogenized in 10 mM HEPES pH 7.9, 10 mM KCl, 3 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM EGTA. The hepatocytes were lysed in the same buer after addition of 0.5% NP40, then nuclei were pelleted and lysed in HEPES 20 mM, NaCl 400 mM, 1 mM EDTA, 1 mM EGTA.
Protein concentrations were standardized using the Bradford assay (BioRad) and equal loading (100 mg/lane) was con®rmed by Coomassie blue staining. Proteins were resolved by SDS ± PAGE and transferred onto nitrocellulose membranes. Western blot analysis was performed using a polyclonal rabbit-anti-mouse antibody directed against Smad2-P and Smad4 protein (Upstate Biotechnology, Lake Placid, NY, USA) followed by goat peroxidase-conjugated anti-rabbit IgG. Immunoreactive proteins were visualized using enhanced chemiluminescence (SuperSignal Chemiluminescent Signal, Pierce, Rockford, US, USA).
